Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

• Status: Completed
• Trial end date: 2018-05-08
• Target enrollment: 0
• Participant gender: All

Summary

This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically significant risks associated with the use of vernakalant in real-world clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardiome Pharma; Correvio International Sarl

Criteria

Inclusion Criteria:

• To be treated with intravenous vernakalant, independently of this study

• Participant and/or legal guardians willing to provide informed consent and/or informed assent according to local regulations

Exclusion Criteria:

• Enrollment in an investigational drug or device clinical trial in the 30 days prior to study enrolment. Participation in another non-interventional drug or device study or registry is permitted.